Beam Therapeutics Inc. (BEAM)
| Market Cap | 2.28B +5.4% |
| Revenue (ttm) | 146.64M +163.3% |
| Net Income | -108.35M |
| EPS | -1.04 |
| Shares Out | 99.67M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,045,050 |
| Open | 24.03 |
| Previous Close | 24.03 |
| Day's Range | 22.81 - 24.06 |
| 52-Week Range | 20.23 - 38.26 |
| Beta | 2.22 |
| Analysts | Strong Buy |
| Price Target | 49.85 (+118.35%) |
| Earnings Date | Nov 3, 2026 |
About BEAM
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylk... [Read more]
Financial Performance
In 2025, Beam Therapeutics's revenue was $139.74 million, an increase of 120.01% compared to the previous year's $63.52 million. Losses were -$79.99 million, -78.77% less than in 2024.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for BEAM stock is "Strong Buy." The 12-month stock price target is $49.85, which is an increase of 118.35% from the latest price.
News
Beam Therapeutics price target raised to $33 from $30 at Wedbush
Wedbush raised the firm’s price target on Beam Therapeutics (BEAM) to $33 from $30 and keeps an Outperform rating on the shares.
Beam Therapeutics reports BEACON trial achieves primary efficacy endpoint
Beam Therapeutics (BEAM) announced topline results from the BEACON Phase 1/2 study evaluating ristoglogene autogetemcel in patients with sickle cell disease with severe vaso-occlusive crises. Risto-ce...
Beam Therapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
BEACON met all primary and secondary endpoints, with a BLA targeted by year-end 2026 and a risto-cel launch expected in 2027. BEAM-302 is in pivotal development, while PKU and BEAM-301 advance toward broader one-time gene-editing treatments.
Beam Therapeutics Announces Positive Topline Pivotal Data from BEACON Phase 1/2 Trial of Risto-cel in Patients with Sickle Cell Disease
BEACON Trial Achieved Primary Efficacy Endpoint of Freedom from Severe Vaso-occlusive Crises (VOCs) for at Least 12 Consecutive Months, Based on Independently Adjudicated Results, and Met All Primary ...
Beam Therapeutics price target lowered to $51 from $55 at Guggenheim
Guggenheim lowered the firm’s price target on Beam Therapeutics (BEAM) to $51 from $55 and keeps a Buy rating on the shares.
Beam Therapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology (ASH) Annual Meeting
BEACON Trial Results Selected for Official ASH Press Program Initial Patient-Reported Outcomes Demonstrate Early and Sustained Improvements in Physical Function, Pain, Fatigue, Emotional and Social We...
Beam Therapeutics price target lowered to $41 from $43 at BofA
BofA lowered the firm’s price target on Beam Therapeutics (BEAM) to $41 from $43 and keeps a Buy rating on the shares.
Beam Therapeutics price target raised to $30 from $28 at Wedbush
Wedbush raised the firm’s price target on Beam Therapeutics (BEAM) to $30 from $28 and keeps an Outperform rating on the shares after the company reported Q3 earnings and highlighted…
Beam Therapeutics price target lowered to $78 from $79 at Canaccord
Canaccord analyst Whitney Ijem lowered the firm’s price target on Beam Therapeutics (BEAM) to $78 from $79 and keeps a Buy rating on the shares. The firm said there wasnt…
Beam Therapeutics price target raised to $49 from $41 at Jefferies
Jefferies analyst Maury Raycroft raised the firm’s price target on Beam Therapeutics (BEAM) to $49 from $41 and keeps a Buy rating on the shares. For AATD, management is confident…
Beam Therapeutics reports Q3 EPS ($1.28), consensus ($1.17)
Reports Q3 revenue $307,000, consensus $9.96M. “Our progress this quarter reflects the growing maturity and momentum of Beam‘s platform, with predictable clinical translation across four distinct prog...
Beam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress Across Base Editing Portfolio
Updated BEAM-302 Phase 1/2 Clinical Data Presented at ERS Demonstrated Durable Increases in Functional AAT and Reductions in Mutant Z-AAT; Completion of Dosing in the Global Pivotal Cohort Expected in...
Beam Therapeutics Quarterly report: Q3 2026
Beam Therapeutics has published its Q3 2026 quarterly earnings report on November 3, 2026.
Beam Therapeutics Earnings release: Q3 2026
Beam Therapeutics released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Beam Therapeutics price target raised to $79 from $78 at Canaccord
Canaccord raised the firm’s price target on Beam Therapeutics (BEAM) to $79 from $78 and keeps a Buy rating on the shares. The firm updated its model after the company…
H.C. Wainwright says Beam Therapeutics data strengthens confidence
H.C. Wainwright analyst Patrick Trucchio reiterates a Buy rating on Beam Therapeutics (BEAM) with an $80 price target following the initial data from BEAM-301 trial. The data presented today at…
Beam Therapeutics Transcript: Study result
BEAM-301 showed clinical proof of concept in GSD1a: 2 of 3 patients at 40 mg fasted for 15 hours and stopped cornstarch. Enrollment at 60 mg is underway, with FDA discussions planned on a potential efficient path forward.
Beam Therapeutics Press release: Study result
Beam Therapeutics issued a press release on October 27, 2026, disclosing material business information to investors.
Beam Therapeutics Slides: Study result
Beam Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on October 27, 2026.
Beam Therapeutics reports initial data from BEAM-301 trial
Beam Therapeutics (BEAM) reported initial data from the ongoing Phase 1/2 clinical trial evaluating BEAM-301 for the treatment of glycogen storage disease type Ia, or GSDIa. The data will be…
Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual Congress
In the 40 mg Cohort, Two Patients Achieved 15 Hours of Controlled Fasting, Improvements in Glucose Control and No Longer Required Starch Supplementation Following Treatment Safety Profile of BEAM-301...
Beam Therapeutics to present initial BEAM-301 data at ESGCT
Beam Therapeutics (BEAM) announced that the company will present initial data from the ongoing Phase 1/2 clinical trial evaluating BEAM-301 for the treatment of glycogen storage disease type Ia, or…
Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congress
BEAM-301 Achieves Clinical Proof of Concept for Genetic Correction of R83C Mutation in GSDIa Initial Phase 1/2 Data Show Restoration of Endogenous Glucose Production Following a Single Treatment, with...
Cathie Wood’s ARK Investment buys 103K shares of Beam Therapeutics today
20:28 EDT Cathie Wood’s ARK Investment buys 103K shares of Beam Therapeutics (BEAM) today
Cathie Wood’s ARK Investment buys 103K shares of Beam Therapeutics today
20:28 EDT Cathie Wood’s ARK Investment buys 103K shares of Beam Therapeutics (BEAM) today